Navigation Links
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
Date:3/14/2011

CRANBURY, N.J., March 14, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

"We are so pleased that Cornerstone has received a report from NCI indicating that Emulsiphan appears to be safe and capable as a drug delivery solution for anticancer agents," said Dr. Robert Shorr, CEO of Cornerstone Pharmaceuticals, Inc.

"Combining anticancer agents with a targeted drug delivery technology, such as Emulsiphan, could greatly improve patient outcomes. We look forward to the next phase of preclinical study in our ongoing collaboration with NCI."

The preclinical study, which looked at the safety of azide drug-loaded Emulsiphan nano emulsions, is the first step in a collaboration between Cornerstone and NCI to apply Cornerstone's drug delivery platform to a class of novel chemotherapy agents developed by Dr. Yossef Raviv in the laboratory of the renowned biologist Dr. Robert Blumenthal at NCI's Center for Cancer Research Nanobiology Program.

Selective drug delivery remains a formidable challenge in the successful treatment of cancer. Often, just a small percentage of the active ingredients in chemotherapies administered to treat tumors ever reach the desired target within cancer cells and considerable amounts of drug spread to healthy cells and tissue.

Emulsiphan is a novel, cancer selective drug-delivery nanotechnology that aims to deposit cancer-fighting drugs directly into cancer cells--not just the tumor mass--by focusing on the distinct metabolism of these cells.  The nanotechnology is designed to maximize drug concentration into tumor cells, thereby enhancing the anti-cancer compounds' selectivity and specificity, leading to a potentially safer and more effective cancer treatment.

About Cornerstone Pharmaceuticals Cornerstone Pharmaceuticals, Inc. is a privately held company committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone currently has a drug in clinical trials targeting enzymes crucial to cancer cell metabolism.  AEMD compounds, the company's unique approach to cancer treatment, is the leading platform in cancer metabolism.  It has facilitated the discovery of first-in-class drugs and a novel drug delivery technology - both with the potential to transform the way cancer is treated.

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.Media Contact: Meghan WeberLiza Sullivan & Associates(917) 399-8713
'/>"/>

SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
2. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
3. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
9. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
10. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
11. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
Breaking Medicine News(10 mins):